FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2393655591> ?p ?o ?g. }

• W2393655591 endingPage "s251" @default.
• W2393655591 startingPage "s250" @default.
• W2393655591 abstract "Introduction Data on clinical outcomes with long-acting antipsychotic treatment in young, newly diagnosed patients with schizophrenia is sparse. Objectives To explore hospitalization, drug utilization and clinical outcomes from medical records of newly diagnosed schizophrenia patients during first 12 months of treatment with once-monthly paliperidone palmitate (PP). Methods International, multicenter, retrospective, observational study. Outcomes presented: baseline (BL) characteristics and demographics, clinically relevant improvements in disease severity (ie ≥ 20% decrease in PANSS or BPRS total score or CGI-S Change ≥ −2 or CGI-C ≥ 3, with no score showing worsening) and clinically relevant functional improvement (i.e. change in PSP total score ≥ +7 points or change in GAF total score ≥ +20 points, with no score showing worsening) from BL to last-observation-carried-forward endpoint (LOCF-EP) within 12-month documentation period, mean mode PP dose and adverse drug reactions. Results Eighty-four patients analyzed: 69% male, mean age at initiation of PP was 24.1 (SD2.7) years, mean BL weight was 78.7 (SD16.0) kg and 80.0 (SD14.7) kg at LOCF-EP, with a mean change of 1.2 (SD3.9) kg; mean time from first psychotic episode to initiation of PP was 5.5 (SD3.3) months. At LOCF-EP 86.6% achieved a clinically relevant improvement (71/84, Kaplan-Meier median time from initiation of PP: 52.4 days). 63.4% achieved a clinically relevant functional improvement (52/84, Kaplan-Meier median time from initiation of PP: 53.1 days). PP mean mode maintenance dose was 96.4 (SD19.8) mg. ADRs reported in ≥ 5% of patients were weight increase 9.1% and hyperprolactinemia 5.7%. Conclusions Treatment with once-monthly PP was well tolerated and associated with clinically relevant improvements in disease severity and functioning in young, newly diagnosed schizophrenia patients. Disclosure of interest The authors have not supplied their declaration of competing interest." @default.
• W2393655591 created "2016-06-24" @default.
• W2393655591 creator A5058880525 @default.
• W2393655591 creator A5068132580 @default.
• W2393655591 creator A5074778675 @default.
• W2393655591 creator A5090231742 @default.
• W2393655591 date "2016-03-01" @default.
• W2393655591 modified "2023-10-18" @default.
• W2393655591 title "Clinical and functional response to paliperidone palmitate in early schizophrenia–A retrospective observational study in newly diagnosed patients treated over a 12-month period" @default.
• W2393655591 doi "https://doi.org/10.1016/j.eurpsy.2016.01.636" @default.
• W2393655591 hasPublicationYear "2016" @default.
• W2393655591 type Work @default.
• W2393655591 sameAs 2393655591 @default.
• W2393655591 citedByCount "1" @default.
• W2393655591 countsByYear W23936555912022 @default.
• W2393655591 crossrefType "journal-article" @default.
• W2393655591 hasAuthorship W2393655591A5058880525 @default.
• W2393655591 hasAuthorship W2393655591A5068132580 @default.
• W2393655591 hasAuthorship W2393655591A5074778675 @default.
• W2393655591 hasAuthorship W2393655591A5090231742 @default.
• W2393655591 hasConcept C118552586 @default.
• W2393655591 hasConcept C126322002 @default.
• W2393655591 hasConcept C167135981 @default.
• W2393655591 hasConcept C197934379 @default.
• W2393655591 hasConcept C23131810 @default.
• W2393655591 hasConcept C2776412080 @default.
• W2393655591 hasConcept C2777126507 @default.
• W2393655591 hasConcept C2780494398 @default.
• W2393655591 hasConcept C2908997079 @default.
• W2393655591 hasConcept C71924100 @default.
• W2393655591 hasConceptScore W2393655591C118552586 @default.
• W2393655591 hasConceptScore W2393655591C126322002 @default.
• W2393655591 hasConceptScore W2393655591C167135981 @default.
• W2393655591 hasConceptScore W2393655591C197934379 @default.
• W2393655591 hasConceptScore W2393655591C23131810 @default.
• W2393655591 hasConceptScore W2393655591C2776412080 @default.
• W2393655591 hasConceptScore W2393655591C2777126507 @default.
• W2393655591 hasConceptScore W2393655591C2780494398 @default.
• W2393655591 hasConceptScore W2393655591C2908997079 @default.
• W2393655591 hasConceptScore W2393655591C71924100 @default.
• W2393655591 hasIssue "S1" @default.
• W2393655591 hasLocation W23936555911 @default.
• W2393655591 hasOpenAccess W2393655591 @default.
• W2393655591 hasPrimaryLocation W23936555911 @default.
• W2393655591 hasRelatedWork W1990041843 @default.
• W2393655591 hasRelatedWork W2058877657 @default.
• W2393655591 hasRelatedWork W2282994664 @default.
• W2393655591 hasRelatedWork W2327601700 @default.
• W2393655591 hasRelatedWork W2360796660 @default.
• W2393655591 hasRelatedWork W2413588599 @default.
• W2393655591 hasRelatedWork W2559559000 @default.
• W2393655591 hasRelatedWork W2896838408 @default.
• W2393655591 hasRelatedWork W4301248676 @default.
• W2393655591 hasRelatedWork W72903313 @default.
• W2393655591 hasVolume "33" @default.
• W2393655591 isParatext "false" @default.
• W2393655591 isRetracted "false" @default.
• W2393655591 magId "2393655591" @default.
• W2393655591 workType "article" @default.